Tres Manos Lab

Tres Manos Lab is a stealth-stage biotechnology company focused on engineering next-generation viral vectors for gene therapy. Founded by Dr. David Schaffer, a pioneer in directed evolution, the company leverages a proprietary platform to create novel Adeno-associated virus (AAV) capsids with improved delivery characteristics. These engineered vectors are designed to achieve higher tissue specificity, evade the immune system, and increase therapeutic potency compared to wild-type AAVs. Based in Berkeley, California, Tres Manos Lab aims to address the delivery challenges that currently limit the reach of gene therapies in treating complex genetic and acquired diseases. The company is currently optimizing its lead candidates and building a pipeline focused on high-unmet-need indications in neurology and ophthalmology.